Online inquiry

IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9945MR)

This product GTTS-WQ9945MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets EPHA3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005233.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2042
UniProt ID P29320
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ9945MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4466MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-901608
GTTS-WQ10437MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ3203MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARGX-110
GTTS-WQ4767MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ3105MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ10934MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MBG-453
GTTS-WQ11677MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ10984MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCDS0593A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW